About Us

About Us

Palisade Bio is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company utilizes over three decades of research and established science that links the role of intestinal barrier biology and human disease to develop novel therapeutics that target and improve the integrity of the intestinal barrier.

The Company’s lead program, LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. In clinical studies, LB1148 has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and accelerating the time to return of postoperative bowel function. LB1148 is being investigated in a Phase 2 study to evaluate return of gastrointestinal function, post-operative ileus and intra-abdominal adhesions in subjects undergoing elective bowel resection (PROFILE).

Intestinal Villi

Leadership Team

Our leadership is comprised of a team of experts in clinical development, commercialization, and pipeline development who are passionate about the advancement of science and medicine.

JD Finley

Interim Chief Executive Officer and Chief Financial Officer

Robert McRae

Senior Vice President, Operations and Strategic Development

Board Of Directors

Clinical Steering Committee

Scientific Advisory Board


The Palisade Bio team is dedicated to developing new therapies for a range of serious, widespread health conditions that impact millions of patients every year. We are driven by science—and supported by a culture of innovation, openness and problem-solving.

Join us in our mission.